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Abstract
Sarcoidosis is a multisystem granulomatous disease, mainly involving the lungs, 
mediastinal and peripheral lymph nodes, liver, eyes, and skin. Cutaneous manifes-
tations of sarcoid are variable and behave as “great imitators” of other cutaneous 
disorders. Cutaneous lesions are classified as specific and nonspecific forms. A 
large number of systemic sarcoidosis patients have specific cutaneous lesions, 
and this may be the presenting feature; isolated skin lesions may also present in 
some patients. Specific lesions of sarcoid are red-brown or red-violaceous in color, 
asymptomatic, and usually multiple in number. Different types of lesions may pres-
ent in the same patient. This clinical appearance is due to the presence of epithelioid 
cell granulomas in the dermis.
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1. Introduction
The granuloma is the result of interplay of an invading organism or antigen, 
chemical, drug or other irritant, prolonged antigenemia, macrophage activity, a Th1 
cell response, B cell overactivity, circulating immune complexes, and a vast array 
of biological mediators [1]. Cutaneous granulomatosis can be localized or more 
disseminated, depending on their etiology. The typical lesion is a painless infiltrated 
papule, rounded, well limited, and reddish-pink and takes a yellowish color on 
diascopy, called apple-jelly. Its surface is smooth or slightly squamous, as there is 
generally no epidermal participation [2]. From a clinical point of view, it is useful 
to divide cutaneous granulomatosis into localized and more disseminated forms, 
although this distinction may sometimes be artificial. From a pathogenic point of 
view, they are divided into noninfectious and infectious granulomas [3].
2. Comprehensive classification of granulomatous disorders
A comprehensive classification of granulomatous disorders of the skin (accord-
ing to American Academy of Dermatology, 76th Annual Meeting San Diego, CA 
USA) (Table 1) [4].
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3. Noninfectious granulomatous disorders
3.1 Epithelioid granulomas
3.1.1 Sarcoidosis
Sarcoidosis is a multiorgan disease. The most commonly affected organs are 
skin, lungs, and lymph nodes. Different epidemiological factors such as age, sex 
and race, the duration of the disease, and the sites of involvement affect the pre-
sentation of sarcoid. Cutaneous manifestations are extremely variable. Lesions 
of sarcoidosis are classified as “specific” (noncaseating granulomas are present in 
biopsy specimens of tissue) or “nonspecific” (lesions develop as a result of a reac-
tive process without the formation of granulomas) [5].
Specific lesions develop in 9–15% of all sarcoidosis patients [5]. These lesions are 
highly variable in presentations and may be confused with many other skin diseases. 
The most frequent specific lesions are papules, plaques, lupus pernio, scar sarcoidosis, 
and subcutaneous sarcoidosis [5]. Erythema nodosum is the most common nonspecific 
lesion which develops in up to 25% of sarcoidosis cases [6]. Women are more com-
monly affected than men (W/M, 2:1) and black people than other ethnic groups [7].
Noninfectious granulomatous disorders Infectious granulomatous disorders
Epithelioid granulomas Caseating granulomas
Sarcoidosis Tuberculosis
Granulomatous rosacea/POD Leprosy
Cutaneous Crohn’s Atypical mycobacterium
Orofacial granulomas Leishmaniasis
Palisading granulomas Suppurative granulomas
Granuloma annulare Deep fungal
Elastolytic giant cell granuloma Pyodermas
Necrobiosis lipoidica Granulomatous STDs
Rheumatic nodules
Reactive granulomatous disorders
Xanthomatous granulomas
Adult onset XG
Adult onset APXG
NXG
Multicentric reticulohistiocytosis
Rosai-Dorfman
Xanthoma disseminatum
Others
Granulomatous vasculitis
Lymphomatoid granulomatosis
Foreign body reactions
Granulomatous drug reactions
Table 1. 
Classification of granulomatous disorders of skin (American Academy of Dermatology, 76th Annual Meeting 
San Diego, CA USA).
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The clinical appearance is due to the presence of epithelioid cell granulomas 
in the dermis. The epidermis rarely appears to be clinically involved [8]. Specific 
lesions are red-brown or red-violaceous in color and generally multiple and do not 
cause any symptoms which on diascopy reveals the brown-yellow or apple-jelly 
color, characteristics of granulomatous diseases. But it is usually more opaque 
than in lupus vulgaris [9]. Different types of cutaneous lesions may coexist in one 
patient.
3.1.1.1 Specific lesions of sarcoid
3.1.1.1.1 Maculopapular sarcoidosis
Lesions of maculopapular sarcoidosis are usually red-brown to purple in color 
and less than 1 cm in diameter. Sometimes they may be skin-colored, yellow-brown, 
or hypopigmented. They are slightly infiltrated, with little epidermal change. They 
are located on the face, particularly on the eyelids, around the orbits and the nasola-
bial folds, and on the scalp, occipital area of the neck, trunk, buttocks, and extremi-
ties (Figure 1). Lesions are commonly disseminated, and mucous membranes may 
even be involved [7, 9–11]. Diascopy shows the typical apple-jelly color characteris-
tic of granulomatous skin lesions. These lesions are sometimes transient and appear 
to herald the onset of the disease [11]. Patients with papular lesions had a mean age 
of 47 years (9–83 years), and the usual duration of disease to heal is less than 2 years 
[12]. Acute organ involvement, such as sudden lymphadenopathy, acute arthritis, 
and acute uveitis abnormal chest radiographs, has been associated with this type of 
Figure 1. 
Papular sarcoid.
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eruption [9]. The intrathoracic involvement occurs in the early stage of the disease, 
bilateral hilar lymphadenopathy with or without parenchymal infiltration (up to 
stage II) (60%), and lymphadenopathy in 50% of the patients [13].
3.1.1.1.2 Nodular and plaque sarcoid
It more commonly develops on the back, buttocks, face, and extensor surfaces 
of the extremities [7]. It is as common as maculopapular sarcoid [10]. It is usually 
present as multiple round or oval, infiltrated reddish-brown plaques [7, 10], larger 
than 10 mm in diameter, more indurated, thicker, and persistent than papular 
sarcoid (Figure 2). Sometimes it is mammillated and can be associated with nodu-
lar dermal lesions [14]. More than 90% of cases are chronic with disease activity 
persisting after 2 years [12].
3.1.1.1.3 Lupus pernio
It is the characteristic cutaneous manifestation of sarcoidosis [15]. Lupus pernio 
refers primarily to diffuse, violaceous to telangiectatic plaque lesions of the nose, 
cheeks, ears, and fingers [16–19] (Figure 3). It tends to appear in older people, 
especially the black women affected more frequently [20, 21]. The lesions enlarge 
and become confluent to form progressively disfiguring nodular plaques on the nose 
and adjacent cheeks [21]. The lesions can involve the upper respiratory tract and 
cause nasal ulceration, obstruction, and perforation of the nasal septum [15, 22, 
23]. Some cases have developed plaques on the arms, thighs, and buttocks [21, 24] 
and sausage-shaped expansion of the phalanges [16, 25]. This form of sarcoidosis 
can be recalcitrant to systemic corticosteroids and other immune-suppressants and 
may be an indicator of current or impending organ involvement [24]. Also it usually 
follows an extremely chronic course—2–25 years in published series [11, 13].
3.1.1.1.4 Scar sarcoid
Scar sarcoid presents as erythematous, cutaneous, or subcutaneous swelling 
in the area of an old scar or beside a scar and the development of papules and 
nodules within the original scars [26]. Scar sarcoidosis can occur on skin sites 
damaged by a range of factors, including mechanical injuries, venipuncture, 
Figure 2. 
Plaque sarcoid.
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intramuscular injections, inoculations, tattoos, and infections such as herpes zoster 
[27] (Figure 4). Foreign material within the scar, deposited by external factors 
including those stated above, is a possible cause of epithelioid granuloma [28]. The 
specific skin lesions that occur and the resulting sarcoidosis may be associated with 
the severity and duration of the disease, with scar sarcoidosis often being accom-
panied by systemic involvement [29]. Alterations, such as further damage or stress 
to the existing scars, often prompt worsening of sarcoidosis [30]. Scar sarcoidosis 
can appear at the onset of disease and must be looked for whenever a diagnosis of 
sarcoid is considered [8]. However, more commonly it is associated with longstand-
ing pulmonary and mediastinal involvement, uveitis, peripheral lymphadenopathy, 
bony cyst, and parotid infiltration [9, 11].
3.1.1.1.5 Subcutaneous sarcoid (Darier-Roussy sarcoid)
Peak incidence of subcutaneous sarcoid is the fourth decade of life; females are 
more affected than male; these are asymptomatic to slightly tender subcutaneous 
lesions typically involving the upper extremities. Majority lessons are erythematous 
(57%), followed by skin colored (30%), hypopigmented, or violaceous [7, 10] 
(Figure 5). Lesions are usually multiple, clustered, and bilaterally asymmetrical 
[32]. There are autoimmune disease associations in a subset of patients. There is 
strong association with a systemic disease component at the outset of disease, 
notably bilateral hilar adenopathy; noninfectious panicular sarcoidal or epithelioid 
granulomas with minimal lymphocytic inflammation; and a favorable response to 
oral corticosteroid therapy [31].
3.1.1.1.6 Less common form of cutaneous sarcoidosis
A wide variety of different cutaneous manifestations have been reported, and 
the clinical pictures are highly heterogeneous.
Annular sarcoid. Annular lesions are well-recognized forms of cutaneous 
sarcoidosis, amounting to around 8% of all skin lesions according to a recent study 
Figure 3. 
Lupus pernio.
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from India [32]. Papular lesions may coalesce or be arranged in annular patterns, 
usually with a red-brown hue. Lesions are indurated, have central clearing with 
hypopigmentation, and atrophy and scarring may occur (Figure 6). Usually, the 
photo-exposed areas that are affected have a predilection for the face, forehead, and 
neck. Alopecia may occur in the center of the lesions [32, 33].
Angiolupoid sarcoidosis. Angiolupoid sarcoidosis is an infrequent variant of 
the disease, affecting 8% of patients with cutaneous sarcoidosis [32]. It manifests 
clinically as single plaques with central hypopigmentation, which eventually acquire 
annular shape with prominent telangiectasias, preferentially located on the face, ears, 
or scalp [32] (Figure 7). It is usually present in women [34]. The cutaneous manifes-
tation may be the first sign of a systemic sarcoidosis with the lung (stage 2) and gland 
involvement that are refractory to several conventional drug therapies [34].
Hypopigmented sarcoid. Dermal nodules with surrounding hypopigmentation 
and macular hypopigmented areas occur predominantly on the limbs. They may be 
tender but have no associated anesthesia [35].
In the nodules, the pigment is retained in the center where the color is dark red-
brown. The lesions are ill-defined, and perifollicular pigment is usually retained at the 
periphery. Nodules are unattached to underlying structures and tender when pressed 
or squeezed [35]. Sarcoid granuloma present in all nodules but in half of macules [36].
Morphea-like lesions. Clinical features are indistinguishable from those of true 
morphea, and the cutaneous lesions may precede or arise years after the extracu-
taneous sarcoidosis [37]. Lesions are coalescing hyperpigmented atrophic plaques, 
may be indurated, usually in limbs, mainly lower limbs [38] (Figure 8).
Figure 4. 
Scar sarcoid.
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Figure 5. 
Subcutaneous sarcoidosis.
Figure 6. 
Annular sarcoid.
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Psoriasiform sarcoidosis. It is a rare morphologic manifestation of sarcoidosis. 
The appearance of its lesion are psoriasiform and infiltrated (Figure 9); some were 
annular, and others followed the natural lines of cleavage of the skin [39]. This type 
of sarcoidosis is usually peculiar to the dark skin [40].
Lichenoid sarcoidosis. About 1–2% of all cases of skin sarcoidosis are in this 
variety. It is characterized by abundant pinhead-sized yellowish lesions closely 
grouped in round or oval clusters, slightly scaling, mimicking lichen planus [41]. 
Lesions can occasionally show superficial scaling (Figure 10a, b). Sites commonly 
involved include trunk, limbs, and face [42]. It appears symmetrically and in crops 
and is associated with the eye and joint complications [41, 43]. The dermoscopy 
findings usually reveal circular or oval yellowish brown lesions with the absence of 
Wickham’s striae. This feature is not specific for sarcoidosis, but such homogeneous 
appearance of lesions indicates a granulomatous skin disease [44].
Ulcerative sarcoidosis. Ulcerative sarcoidosis usually develops from the papulo-
nodular sarcoid lesions by ulceration, but some arose de novo. Ulcers also developed 
in psoriasiform, atrophie, lymphedematous, erythrodermic, verrucous, suppura-
tive, and elephantine lesions [45]. Lesions usually occur in the lower limb, and the 
upper limb may also be affected; sometimes lesions are generalized [45, 46]. Ulcers 
tended to heal with scarring [46] (Figure 11). Women are affected three times more 
than men, and blacks are affected slightly more than whites. Ulcer is a presenting 
feature in nearly 30% of patients, half of them having an initial lesion of other 
types [45], and cutaneous lesions are usually the presenting sign of sarcoidosis [45].
Figure 7. 
Angiolupoid sarcoid.
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Figure 8. 
Morpheaform sarcoidosis.
Figure 9. 
Psoriasisform sarcoidosis.
Sarcoidosis and Granulomatosis - Diagnosis and Management
10
Verrucous sarcoidosis. All reported patients of verrucous sarcoidosis have been 
of African descent with a longstanding systemic disease. Usually, systemic sarcoid-
osis of other internal organs is present [47]. Lesions may be multiple exophytic, 
extensively verrucous yellowish-to-whitish lesions with a reddish-brown circinate 
border, size ranging from 1.0 to 2.0 cm in diameter [48].
3.1.1.2 Nonspecific lesions of sarcoid
Erythema nodosum, the most common nonspecific lesion, develops in 20–25% 
of sarcoidosis cases [6, 49]. Frequently, it is the initial manifestation of disease. It is 
the marker of acute and benign sarcoidosis and tends to affect younger people than 
infiltrative cutaneous lesions [12]. Sarcoidosis is the second most common cause of 
erythema nodosum [50]. If sarcoid is associated with EN, it usually runs a benign 
and self-limited course [51]. Women are affected three to six times more frequently 
than men [52]. EN can occur in all age groups, but it is typically seen between the 
second and fourth decades of life. The higher prevalence of erythema nodosum 
among young people is considered to be due to the higher incidence of sarcoidosis 
in this age group [11]. EN is characterized by sudden onset of symmetric, tender, 
erythematous, warm nodules and raised plaques, usually located on the shins, 
ankles, and knees (Figure 12). Nodules are from 1 to 5 cm or more in diameter and 
Figure 10. 
(a and b) Lichenoid sarcoidosis.
Figure 11. 
Ulcerative sarcoidosis.
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distributed bilaterally. Nodules may become confluent, resulting in erythematous 
plaques. In rare instances, more extensive lesions may appear, involving the thighs, 
extensor aspects of the arms, the neck, and even the face. Initially the nodules are 
bright red in color; within a few days, they become flat, with a livid red or purplish 
color and finally a yellow or greenish appearance, often taking on the look of a deep 
bruise (erythema contusiformis). This contusiformis color evolution is quite char-
acteristic of erythema nodosum and allows a specific diagnosis in late-stage lesions 
[53]. Ulceration is never seen in erythema nodosum, and the nodules heal without 
atrophy or scarring [54]. Usually, acute bouts of erythema nodosum are associated 
with a fever of 38–39°C, fatigue, malaise, arthralgia, headache, abdominal pain, 
vomiting, cough, or diarrhea. Episcleral lesions and phlyctenular conjunctivitis may 
also accompany the cutaneous lesions. Less frequent clinical manifestations associ-
ated with erythema nodosum are lymphadenopathy, hepatomegaly, splenomegaly, 
and pleuritis [55]. Eruption generally lasts from 3 to 6 weeks, but persistence 
beyond this time is not unusual. Recurrences are not uncommon. Erythema nodo-
sum in children has a much shorter duration than in adults, arthralgias are seen in a 
minority of the patients, and fever is an accompanying manifestation in fewer than 
half of the cases [56].
Another nonspecific lesion of sarcoid is Lofgren’s syndrome, an acute form of 
sarcoidosis characterized by erythema nodosum, bilateral hilar lymphadenopathy 
(BHL), and symmetric polyarthritis [57]. Arthritis in sarcoidosis is usually sym-
metrical; the ankles are involved in more than 90% of the cases; the knees, small 
joints of the hands or feet, wrists, and elbows are involved in 15–40% [58–60]. Local 
pain, soft-tissue swelling, periarticular tenderness, edema, and joint effusion may 
be present [61]. In 1953, Lofgren characterized 212 adult patients of bilateral hilar 
lymphadenopathy who were practically regarded as having sarcoidosis based on the 
absence of tuberculosis. Lofgren demonstrated that EN was present at the onset of 
Figure 12. 
Erythema nodosum.
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the disease in 113 cases in which articular symptoms were common (101 cases, 89%). 
There was either pain only in the joints (20%) or pain accompanied by swelling 
(69%) [62]. Lofgren’s syndrome was regarded as a self-limiting disease that is gener-
ally resolved within the first year, with the mean duration ranging from 3 weeks to 
3.7 months [57, 60]. However, 8% of patients had active symptoms 2 years after the 
onset; 6% had episodes of recurrent sarcoidosis 2.20 years after the diagnosis [62].
3.1.2 Granulomatous rosacea
Granulomatous rosacea is a distinct variant of rosacea. Lewandowsky described 
the “rosacea-like tuberculid” as having a clinical appearance similar to that of 
a papular form of rosacea; however, it appeared as yellow-brown “apple-jelly” 
nodules on diascopy and as tuberculoid granulomas on histologic examination [63]. 
Later it was noted that granulomas can be seen in typical rosacea [64]. Thus rosacea 
may be manifested by a clinical and a histologic spectrum that includes granuloma 
formation in some patients [65]. Lesions are persistent, firm, and non-tender; red 
to brown papule or nodule arises primarily on otherwise normal appearing skin 
around the mouth and eyes and on the cheeks [66] (Figure 13). Granulomatous 
rosacea often does not present facial erythema, is not limited to facial convexities, 
often has periocular lesions, and shows an asymmetrical distribution [67]. Some 
studies have demonstrated that patients with this variant present clinically with 
monomorphic yellow-brown and red papules or nodules situated predominantly 
over the cheeks and periorificial areas [68, 69]. Although clinical correlation is 
important, the diagnosis of GR is dependent upon the histopathologic finding of a 
granulomatous infiltrate [70, 71].
3.1.3 Cutaneous Crohn’s disease
Skin manifestations of Crohn’s disease (CD) have been classified into three 
principal classes: granulomatous or CD specific, reactive, and secondary to 
nutritional deficiency [72]. CD-specific lesions account for the majority of lesions 
Figure 13. 
Granulomatous rosacea.
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observed. The best recognized are perianal and peristomal fissures and fistulae 
and oral disease [73]. Skin lesions commonly complicate CD with reported 
prevalence rates as high as 44% [74–76]. The characteristic lesions of metastatic 
Crohn’s diseases are erythematous plaques and nodules and cutaneous ulceration. 
Secondary features like scale or crust may present [73] (Figure 14). Lesions involv-
ing intertriginous and genital skin usually ulcerate, owing to friction [77]. Lesions 
may be solitary or multiple, usually asymptomatic, but may be tender on palpation 
[77]. The oral manifestation of CD in the buccal mucosa is cobblestoning, while the 
gingival and alveolar mucosae often have tiny nodules. Linear ulcers are more com-
mon in sulci. The lips may become swollen, hardened, or ulcerated, especially at 
the angles of the mouth [78]. Genital lesions are the most common presentation of 
MCD in children; 85% of the cases present with swelling and/or induration of the 
genitals with or without erythema. In adults, the most frequent lesions are nodules 
and plaques, with or without ulceration on the arms and legs, followed by ulcers on 
the genitals [77].
3.1.4 Orofacial granulomatosis
The term orofacial granulomatosis (OFG) includes a group of disorders showing 
chronic, noncaseating granulomatous lesions involving the perioral tissue of the 
face and oral mucosa [79]. Possible systemic diseases, such as tuberculosis, sarcoid-
osis, and other diseases with the same clinical findings are to be excluded before to 
diagnose orofacial granuloma [80]. Clinically, OFG generally presents as swelling 
of upper and/lower lip, even the whole orofacial region including the chin, cheeks, 
periorbital and zygomatic tissues, eyelids, and forehead, unilaterally or bilaterally, 
either alone or in combination, though classic presentation is that of a non-tender 
recurrent labial swelling that may eventually become persistent [79] (Figure 15). 
Furthermore, manifestations include angular cheilitis, mucosal ulcerations, verti-
cal fissures of the lips, mucosal tags, and lingua plicata [81]. However, the clinical 
Figure 14. 
Metastatic Crohn’s disease.
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presentation can be highly variable, making the diagnosis difficult to establish, i.e., 
intraoral involvement may take the form of hypertrophy, erythema, or nonspecific 
erosions involving the gingiva, oral mucosa, or tongue [80–82]. Clinicopathological 
correlation is required for final diagnosis.
3.2 Palisading granulomas
3.2.1 Granuloma annulare
It is characterized by ringed erythematous plaques with granulomatous inflam-
mation seen histologically. There are four clinical variants of GA-localized, general-
ized, or disseminated, subcutaneous, and perforating [83].
The localized, commonest variety, nearly three-fourths of all GA cases, is in 
this group. Lesions are usually present as skin-colored or erythematous papules, 
without epidermal change, that are often arranged in arciform or annular patterns, 
usually less than 5 cm in diameter, and enlarge centrifugally [84–86] (Figure 16). 
Subcutaneous and superficial papular lesions may coexist in some patients, 
particularly in children [84]. The number of lesions may be single or multiple, 
in equal distribution. The commonest site of involvement is the hands and arms 
(63%), lower extremity in 20%, trunk alone in 5%, and all extremities affected 
in 7% of patients. Both sexes are equally affected [84]. Lesions are temporary in 
70% of cases. In 51%, clearing happens within 2 years. The age of the patients did 
not affect the prognosis to any great extent, and usually three-fourths of patients 
recover [84].
In generalized (disseminated) granuloma annulare, innumerable number of 
lesions, arranged in symmetrical distribution, presents in any part of the body, 
but the face and also the palm and sole are usually spared. There may be mac-
ules, papules, or nodules [84], arranged in an annular fashion [86]; colors range 
from skin-tone to red, yellow, or tan. There is controversy about generalized and 
disseminated GA. In original description, granuloma annulare was defined as 
Figure 15. 
Orofacial Granulomatosis.
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generalized involvement of at least the trunk and the upper or lower extremities [86] 
(Figure 17a, b). It is asymptotic and usually persists for 3–4 years but may persist up 
to 10 years and recur [84]. The age of onset is bimodal in distribution, with 80% of 
patients presenting in the fourth to seventh decades and the remainder presenting 
before the age of 10 [84]. Female to male ratio is slightly higher [86].
Subcutaneous granuloma annulare, also known as pseudorheumatoid nodule, 
is a self-limiting disorder usually found between the ages of 3 and 6 years, and the 
sex ratio is 1:1 [84, 87, 88]. They are small, pinkish, asymptomatic, hard-elastic, 
nodular, isolated lesions, or associated with local annular granuloma. The overly-
ing skin is healthy. Sites include the pretibial region, elbow, forearm, forehead, 
scalp, and dorsal surfaces of the hands and feet [84] (Figure 18). Lesions situated 
on the head adhere to the periosteum and are fixed with respect to the underly-
ing layers, whereas those on the extremities adhere to the fascia and are therefore 
mobile [84, 89].
Figure 16. 
Granuloma annulare.
Figure 17. 
(a and b) Generalized granuloma annulare.
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3.2.2 Annular elastolytic giant cell granuloma
It is usually a disease of middle-aged, Caucasian women [90]. Onset is sudden 
but progressive, and varying in duration from 1 month to 10 years [91]. Clinically, 
AEGCG presents as multiple, large, annular plaques with a raised, erythematous 
border and central atrophy. The lesions are mostly located on sun-exposed areas 
such as the face and neck, but they are also seen on nonexposed skin although rare 
reports of a papular variant of AEGCG exist [92, 93]. It is currently unclear whether 
they simply represent a variant of granuloma annulare occurring on sun-damaged 
skin or distinct disease. There are two patterns. One is a single, asymptomatic, atro-
phic-appearing, yellow thin plaque on forehead, and the other is multiple, upper 
extremity, and trunk lesions occurring mainly on sun-exposed areas predominantly 
in women (Figure 19). A papular and arciform variant is also described [90, 91]. 
The histopathologic features are best demonstrated by a biopsy of the elevated edge 
of the plaque [94]. The lesions may persist for months to years resolving with either 
mottled pigmentation or normal-appearing skin [95]. Association with temporal 
arteritis is reported [96]. There have been reported cases of AEGCG associated with 
diabetes, sarcoidosis, and hematological malignancies [97, 98]. Patient of AEGCG 
may associate with Barrett’s esophagus. The patient had hepatic nodules that 
showed nonspecific granulomas with elastolysis, similar to the skin lesions [99].
Figure 18. 
Subcutaneous granuloma annulare.
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3.2.3 Necrobiosis lipoidica
Necrobiosis lipoidica developed in the fourth decade of life and, in type 1 dia-
betes mellitus, in the third decade [100, 101]. Females are more affected than male 
(3:1). It is rare in childhood. NL is usually present on bilateral lower extremities, 
typically pretibial skin, but face, scalp, trunk, groin, and upper extremities can also 
be affected.
It forms as well-circumscribed papules and nodules with active erythematous 
borders that slowly coalesce into plaques. The plaques appear violaceous and con-
tain a central area that initially appears red-brown but later progresses to a yellow-
brown discoloration with atrophic, waxy appearance with prominent telangiectatic 
vessels [102]. But this classical presentation may not present in Indian patients 
where common presentation is erythematous plaque [103] (Figure 20). Lesions are 
1–3 in number [102]. They are usually asymptomatic but may be painful or hypoes-
thetic or anesthetic [104]. NL lesions can also exhibit the Koebner phenomenon. Up 
to one-thirds of the patients with NL may develop ulcerations secondary to minor 
trauma [100]. Occasional reports of squamous cell carcinoma arising in areas of 
long-term lesions have also been reported [105].
3.2.4 Rheumatoid nodule
Rheumatoid nodules are commonly found in patients with rheumatoid arthritis as 
later manifestation of active arthritic disease [106]. It occurs as subcutaneous nodules; 
Figure 19. 
Annular elastolytic giant cell granuloma.
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the most common extra-articular feature of RA [107, 108] is present in about 25–42% 
[107, 108] of RA patients, although similar nodules have been observed in nonrheu-
matoid conditions, such as granuloma annulare and necrobiosis lipoidica [109]. 
Nodules are skin colored, can be solitary or multiple, and range from <5 mm to many 
centimeters in diameter [106] (Figure 21). They lie deeply subcutaneously and can 
adhere to underlying periosteum, tendons, or bursae, although others may be epider-
mal and freely movable [110]. Most are firm and painless and often go unnoticed by 
the average patient, but those found on the plantar surfaces of the feet or palms may 
feel uncomfortable [110].
3.2.5 Reactive granulomatous disorders
Reactive granulomatous disorders are reactive granulomatous processes, which 
present with a cutaneous granulomatous eruptions in response to medications, 
autoimmune disease, arthritides, and internal malignancies. There is a wide spec-
trum of clinical morphologic patterns and a broad array of histologic subtypes 
that may occur. The common RGDs are palisaded neutrophilic and granulomatous 
dermatitis (PNGD), interstitial granulomatous dermatitis (IGD), and interstitial 
granulomatous drug reaction (IGDR) [111].
The classic clinical presentation of PNGD is that of flesh-colored to erythema-
tous papules, which may be umbilicated or crusted, appearing symmetrically on the 
extremities particularly around the elbows [112–114] (Figure 22). Palisaded neutro-
philic and granulomatous dermatitis is seen in association with a number of systemic 
diseases. The diseases most commonly reported with PNGD include connective tis-
sue diseases—particularly systemic lupus erythematosus—as well as inflammatory 
arthritis, hematologic disorders, and rarely infections or medications [111]. Patients 
Figure 20. 
Necrobiosis lipoidica.
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of all ages may develop PNGD, although reports in childhood are rare [114]. Women 
are affected more frequently (approximately 3:1 ratio), likely owing to the systemic 
diseases associated with PNGD [114].
In interstitial granulomatous dermatitis (IGD), the initial description was linear 
subcutaneous cords or bands on the proximal trunk [115], and also erythematous 
to violaceous patches or plaques symmetrically on the upper trunk and proximal 
limbs are a frequent manifestation [116]. IGD is generally seen in the setting of an 
underlying systemic disease, similar to PNGD [111].
There is contradiction whether interstitial granulomatous drug reaction (IGDR) 
is another entity or subtype of interstitial granulomatous dermatitis [111]. The 
classic description of IGDR is erythematous to violaceous plaques, often annular, 
concentrated on the inner arms, proximal medial thighs, proximal trunk, and 
intertriginous sites, with distinctive histologic features [117].
3.3 Xanthomatous granulomas
3.3.1 Adult-onset xanthogranuloma
Xanthogranuloma (XG) is the most common non-Langerhans cell histiocytosis, 
which usually occurs in the early part of life [118]. It is rare in adults, usually occur-
ring in the third and fourth decades of life [119].
Figure 21. 
Rheumatoid nodule.
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Lesions of XG are usually orange or erythematous-brown papule nodule [120], 
varying the tonality with the age of the lesions [118]. XGA usually occurs as a 
single lesion in 2/3 of cases located on the face but may be seen in the trunk or 
limbs [119, 121].
There are three recognized main clinical forms of adult onset xanthogranuloma: 
a small nodular/papular (2–5 mm); large nodular (5–20 mm); and giant xantho-
granuloma (more than 20 mm [122]). Multiple adult onset xanthogranuloma is 
defined when there are more than five XG lesions. It appears to be more common 
among men [121].
3.3.2 Adult onset asthma with periorbital xanthogranuloma (adult onset APXG)
Adult onset asthma with periorbital granuloma (AAPOX) syndrome was first 
described in 1993 by Jakobiec et al. and is considered to be a periorbital disease with 
a specific granulomatous inflammation [123, 124].
Skin surrounding the orbit is yellow-orange in color, with swelling of mainly 
upper and also lower eyelid with compromised eyelid movement. There is associ-
ated allergic sinusitis and adult onset asthma [125].
3.3.3 Necrobiotic xanthogranuloma
It is a chronic, progressive granulomatous disorder with cutaneous and extra-
cutaneous involvement. The mean age is 61.6 years [126]. The mean (SD) age at 
presentation was 61.6 (14.2) years; females are more commonly affected (62.6%) 
than male. Most patients are white (87%) [126]. More than one site is usually 
involved [127].
Figure 22. 
Palisaded neutrophilic and granulomatous dermatitis.
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It usually manifests as yellowish or yellow-orange, red or brown papules, 
plaques, and nodules [126]. The commonest site of involvement is the perior-
bital area [128]. Trunk [127] and also the extremities [126] are the second most 
 common site.
Dermatologic symptoms may present up to 60% of patients such as itching, 
burning, tenderness, and pain. Nearly half of patients may ulcerate, the most com-
mon secondary feature [126, 127].
3.3.4 Multicentric reticulohistiocytosis
It is a rare histiocytic proliferative disease in which joints, skin, mucous mem-
branes, and internal organs are affected [129]. Onset is usually insidious; cutaneous 
manifestations usually follow the articular signs and symptoms [130].
The peak occurrence is seen in middle age with the average age of 40–50 years at 
presentation, but MRH can present at any age [131–133].
The classic skin lesions are firm brown or yellow papule and plaque. Extensor 
surfaces are predominantly affected, particularly on the hands and forearm, and 
also the face, scalp, hands, and ears are often affected, but involvement of lower 
trunk and legs is rare. Coral bead-like lesions may occur around the nail folds which 
may lead to nail dystrophy. The size varies from a few millimeters to centimeters 
[134]. Lesions in proximity to joints may be largely nodular. Lesions may ulcerate. 
The vermicular erythematous lesions around the nostrils are thought to be a charac-
teristic of MRH [135]. Mucosal lesions present from 30 to 50% patients [131, 133], 
oral and nasal mucosa are the frequently involved sites, but lesions may be distrib-
uted along the lips, buccal mucosa, tongue, and gingival and nasal septum. Usually 
lesions are asymptomatic; around 25% patients complain of pruritus.
3.3.5 Rosai-Dorfman syndrome
The hallmark of Rosai-Dorfman disease is massive cervical lymphadenopathy. 
Other lymph node groups like axillary, inguinal, and mediastinal nodes may also be 
affected. In about 10% of patients, the cutaneous manifestations present, which are 
asymptomatic xanthoma-like, yellowish, or reddish-brown papules, nodules, and 
plaques which may ulcerate [136]. Involvement of extra-nodal sites like the nasal 
cavity, paranasal sinuses, eyelids, orbit, skeletal system, salivary glands, and central 
nervous system has been reported [137, 138]. Fever, elevated ESR, neutrophilia, and 
polyclonal gammopathy are other common associations.
3.3.6 Xanthoma disseminatum
It occurs in children and adults and characterized by disseminated xantho-
matous lesions. XD usually presents as erythematous, yellow brown papule and 
nodules, symmetrical in distribution. Lesions become confluent, sometimes form a 
xanthomatous plaque, and may become verrucous [139].
It usually starts before the age of 25 years in about 60% of patients. It is more 
common in males. It may occur anywhere on the body including the scalp, face, 
trunk, and extremities [140].
XD typically involves the skin, particularly the flexor folds, face, and trunk. It 
may also manifest in the central nervous system [141].
Mucous membrane involvement develops in 40–60% of patients, most com-
monly affecting the oropharynx, larynx, or cornea and conjunctiva [142].
There are three clinical patterns of xanthoma disseminatum: (i) a common 
persistent form in which lesions may never resolve; (ii) a rare, self-healing form 
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with spontaneous resolution; and (iii) a very rare, progressive form with organ 
dysfunction and central nervous system involvement [143].
3.4 Other granulomatous disorders
3.4.1 Granulomatous vasculitis
Granulomatous vasculitis is a spectrum of diseases. Lung involvement is very 
much common in GV. Small vessel vasculitis with granulomatosis is seen in granulo-
matosis with polyangiitis (Wegener granulomatosis) and eosinophilic granuloma-
tosis with polyangiitis (Churg-Strauss syndrome), and large-vessel vasculitis with 
granulomatosis is seen in temporal arteritis: Takayasu arteritis.
In Wegener granulomatosis, the incidence of skin disease is 45% [144]. The lesions 
can take several forms including papules, vesicles, palpable purpura, ulcers, and 
subcutaneous nodules [145]. Palpable purpura may be the most frequent (47%) skin 
finding [146]. The skin disease rarely dominates the clinical picture and is usually a 
minor part of the multisystem involvement, generally responds promptly to therapy, 
and parallels disease activity in other organ systems [147]. Other organs include the 
lungs, kidney, heart, joint, eye, and nervous system involvement [148]. Cutaneous 
findings are variable and nonspecific and usually affect the lower extremities [146].
Eosinophilic granulomatosis with polyangiitis was previously named as Churg-
Strauss syndrome. In one-third to two-thirds of patients, skin involvement is a 
dominant feature and presents in the form of nodules. Urticaria and ulceration are 
less common. Neurologic involvement is seen in 60–70% patients and is commonly 
in the form of multiple mononeuropathies or symmetric polyneuropathy [149].
3.4.2 Lymphomatoid granulomatosis
Lymphomatoid granulomatosis (LYG) is a progressive lymphoproliferative 
disease by Epstein-Barr virus (EBV), in which the abnormal cells directly accumulate 
within affected tissues, usually in the form of infiltrative nodular lesions and with 
T-cell invasion and destruction of blood vessels [150]. Its incidence is low, clinical 
features are overlapping, pulmonary disorders are more common, and all contribute 
to frequent delays in diagnosis [150]. The lung is virtually always involved in bilateral 
fashion [151]. The skin is the extrapulmonary organ most commonly involved in LYG, 
occurring in 40–50% of patients [151]. Skin manifestations of LYG are quite heteroge-
neous. They typically appear as scattered subcutaneous or dermal nodules that vary in 
size, seen predominantly on the extremities. Erythematous or purplish maculopapu-
lar eruptions are the most common skin lesions observed, but some patients will have 
indurated plaques. Varying degrees of ulceration accompany the skin lesions and may 
become necrotic when the disease is not well controlled (Figure 23). In up to 10% of 
patients, the skin lesions will antedate the lung lesions, and, in these cases, dermal 
biopsy may lead to the diagnosis [150]. Skin lesion may develop after lung involve-
ment, but majority of skin lesions develop at the time of lung involvement [151].
3.4.3 Foreign body reactions
The foreign body granuloma is a response of biological tissue to any foreign mate-
rial in the tissue [152]. Foreign body granulomas may be due to reactions of endog-
enous products like keratin, hair, fat, urate crystals, mineral, and/or oil products; 
plant and animal products; and synthetic agents [153]. Depending on the individual 
host response and type of foreign materials, clinical findings can be variable. Sites 
depend on the area involved by endo- or exogenous material. The lesions may be 
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asymptomatic or tender, pink, red, red-brown or skin-colored, and firm papules, nod-
ules, or plaques, which may or may not ulcerate or drain (Figure 24). Other presenta-
tions include sinus tracts and abscesses [153]. The foreign material may migrate, as in 
silicone, leading to granulomas at sites distant from the area of implantation [154].
Figure 23. 
Lymphomatoid granulomatosis.
Figure 24. 
Foreign body granuloma.
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3.4.4 Granulomatous drug reactions
Granulomatous drug reactions include four major types: interstitial granuloma-
tous drug reaction, drug-induced accelerated rheumatoid nodulosis, drug-induced 
granuloma annulare, and drug-induced sarcoidosis [155].
The most common cutaneous features of interstitial granulomatous drug 
reaction are symptomatic erythematous plaques and papules with a predilection 
for the flexures (intertriginous areas, medial thighs, and inner aspects of the arms) 
[117]. Trunks also may be involved [117]. Sharply demarcated symmetrical annular 
erythematous lesions [155] are also described. Lesions may be generalized [117]. 
Interstitial granulomatous drug reaction completely regresses with drug cessation 
[155]. Other drug-induced granulomatous disorders are drug-induced accelerated 
rheumatoid nodulosis, with development of tender subcutaneous lesions during 
treatment with methotrexate, and drug-induced granuloma annulare (GA), mainly 
generalized, developed with paroxetine and drug-induced sarcoidosis [156]. Drug-
induced lesions are similar to the original lesions.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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